ACADIA Pharmaceuticals Inc. (ACAD) Cash Flow Statement

The 2025Q4 net income of $273.6M against operating cash flow of negative $48.7M suggests the reported profit was driven by non-cash or non-operating items rather than collected receipts. Conversely, the 2026Q1 ratio above 9 implies that cash collections or working capital releases substantially outran the modest $3.6M in reported earnings. Investors should monitor whether this timing noise averages out over a full cycle or reflects persistent accrual-driven earnings.

The most recent quarter, 2026Q3, delivered only a 3.0% FCF margin despite strong reported revenue, implying that working capital absorption of $77.5M consumed most of the operating cash generated. The two-quarter stretch of $124.5M and $10.3M FCF suggests the trajectory is being driven more by timing than by structural margin change. Analysts should weight trailing multi-quarter averages rather than any single period when assessing cash generation durability.

A $77.5M working capital outflow in 2026Q3 alongside revenue growth may suggest receivable build-up tied to gross-to-net timing or distributor inventory accumulation, though the filings alone cannot confirm which. The reversal pattern across 2026Q1 and 2026Q2 implies that these balances may be unwinding, but this inference warrants further investigation against receivable aging and specialty pharmacy inventory disclosures.

The 2025Q1 and 2025Q2 CapEx intensities of 40.5% and 37.2% of revenue appear anomalous against the near-zero baseline and may reflect a discrete facility or equipment outlay rather than recurring maintenance spending. Depreciation of roughly $3M per quarter sits well above the typical CapEx run-rate, which suggests the asset base is modest and that reinvestment needs are unlikely to be the binding constraint on free cash flow.

Because SBC is added back in deriving operating cash flow, the cash-based profitability appears stronger than the cash cost of the workforce would imply. Investors should consider whether repurchases or dilution offset this expense over time, since no buybacks appear in the reported ten-quarter period. Treating SBC as a real operating cost would likely lower the normalized free cash flow figure.